XTX501 / Xilio Therap - LARVOL DELTA

XTX501: masked PD-1/IL-2 bispecific (GlobeNewswire) - "Xilio is continuing to advance XTX501 in investigational new drug (IND)-enabling studies and plans to submit an IND application for XTX501 in the middle of 2026."

IND • Solid Tumor

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results (GlobeNewswire) - "R&D expenses were $8.3 million for the quarter ended March 31, 2025, compared to $10.4 million for the quarter ended March 31, 2024. The decrease was primarily driven by decreased clinical development activities for XTX202, a masked IL-2, as a result of discontinuing further investment in XTX202, decreased personnel-related costs due to lower headcount and decreased manufacturing costs for XTX301, partially offset by increased spending related to early stage programs and indirect research and development, increased clinical development activities for vilastobart and manufacturing activities for XTX501 in connection with IND-enabling studies."

Commercial • Colorectal Cancer • Oncology

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results (GlobeNewswire) - "Xilio is currently advancing XTX501 in investigational new drug (IND) enabling studies and plans to submit an IND application for XTX501 in the middle of 2026."

IND • Oncology

Pipeline and Business Updates: XTX501 (GlobeNewswire) - "Xilio is currently advancing XTX501 in investigational new drug (IND) application enabling studies and plans to submit an IND application for XTX501 in the middle of 2026."

IND • Oncology • Solid Tumor

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) - "Xilio today reaffirmed plans to report Phase 1 safety, pharmacokinetic and pharmacodynamic data for XTX301 in patients with advanced solid tumors in the fourth quarter of 2024.....Preclinical data from the company’s first bispecific program, XTX501, a tumor-activated PD-1/IL-2 bispecific development candidate, will be featured at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California from April 5-10, 2024."

P1 data • Preclinical • Solid Tumor